Sarepta Therapeutics, Inc.
https://www.sarepta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sarepta Therapeutics, Inc.
News We’re Watching: Telehealth Advances; AI Regulation; NIH Backs SIRT; Oura Upgraded
This week, a House subcommittee advanced a two-year telehealth extension, Chuck Schumer and a bipartisan group of senators introduced a plan for regulating AI, the FDA launched its new online RST Catalog, NIH recommends targeted radiotherapy cancer treatment, and Oura announced new health features for its smart ring.
Development Versus Dealmaking: How To Obtain A Blockbuster
Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.
Medtronic Adds AI In Reveal Linq Device To Reduce False Alerts
Medtronic expects that its new AI-powered Reveal Linq insertable cardiac monitor will be able to reduce the number of false AFib and pause alerts by more than 85%.
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AVI BioPharma, Inc.
- Ercole Biotech, Inc.
- Myonexus Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice